These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 37011093

  • 1. The delayed clearance of Talaromyces marneffei in blood culture may be associated with higher MIC of voriconazole after antifungal therapy among AIDS patients with talaromycosis.
    Guo P, Chen W, Chen S, Chen M, Hu F, Chen X, Cai W, Tang X, Li L.
    PLoS Negl Trop Dis; 2023 Apr; 17(4):e0011201. PubMed ID: 37011093
    [Abstract] [Full Text] [Related]

  • 2. Successful voriconazole treatment of Talaromyces marneffei infection in an HIV-negative patient with osteolytic lesions.
    Ge Y, Xu Z, Hu Y, Huang M.
    J Infect Chemother; 2019 Mar; 25(3):204-207. PubMed ID: 30195473
    [Abstract] [Full Text] [Related]

  • 3. Voriconazole Versus Amphotericin B as Induction Therapy for Talaromycosis in HIV/AIDS Patients: A Retrospective Study.
    Huang W, Li T, Zhou C, Wei F, Cao C, Jiang J.
    Mycopathologia; 2021 May; 186(2):269-276. PubMed ID: 33616828
    [Abstract] [Full Text] [Related]

  • 4. Susceptibility profile of echinocandins, azoles and amphotericin B against yeast phase of Talaromyces marneffei isolated from HIV-infected patients in Guangdong, China.
    Lei HL, Li LH, Chen WS, Song WN, He Y, Hu FY, Chen XJ, Cai WP, Tang XP.
    Eur J Clin Microbiol Infect Dis; 2018 Jun; 37(6):1099-1102. PubMed ID: 29536323
    [Abstract] [Full Text] [Related]

  • 5. Clinical usefulness of metagenomic next-generation sequencing for Talaromyces marneffei diagnosis in China: a retrospective study.
    Zhang X, Yao X, Chen H, Yang M, Han D.
    Eur J Clin Microbiol Infect Dis; 2024 Jul; 43(7):1367-1374. PubMed ID: 38801485
    [Abstract] [Full Text] [Related]

  • 6. Characteristics and Prognosis of Talaromyces marneffei Infection in HIV-positive Children in Southern China.
    Xue X, Zou J, Fang W, Liu X, Chen M, Arastehfar A, Ilkit M, Zheng Y, Qin J, Peng Z, Hu D, Liao W, Pan W.
    Mycopathologia; 2022 Jun; 187(2-3):169-180. PubMed ID: 35157189
    [Abstract] [Full Text] [Related]

  • 7. Talaromyces marneffei Mp1p Antigen Detection may Play an Important Role in the Early Diagnosis of Talaromycosis in Patients with Acquired Immunodeficiency Syndrome.
    Chen X, Ou X, Wang H, Li L, Guo P, Chen X, Cai W, Tang X, Li L.
    Mycopathologia; 2022 Jun; 187(2-3):205-215. PubMed ID: 35237935
    [Abstract] [Full Text] [Related]

  • 8. Characteristics of Endemic Mycoses Talaromyces marneffei Infection Associated with Inborn Errors of Immunity.
    Xing S, Zhang Z, Liu C, Zhang W, Zhang Z, Tang X, Chen Y, He W, Zhao X, An Y.
    J Clin Immunol; 2024 Sep 26; 45(1):17. PubMed ID: 39325235
    [Abstract] [Full Text] [Related]

  • 9. Characteristics and Prognosis of Talaromyces marneffei Infection in Non-HIV-Infected Children in Southern China.
    Guo J, Li BK, Li TM, Wei FL, Fu YJ, Zheng YQ, Pan KS, Huang CY, Cao CW.
    Mycopathologia; 2019 Dec 26; 184(6):735-745. PubMed ID: 31473910
    [Abstract] [Full Text] [Related]

  • 10. Machine learning-based in-hospital mortality prediction of HIV/AIDS patients with Talaromyces marneffei infection in Guangxi, China.
    Shi M, Lin J, Wei W, Qin Y, Meng S, Chen X, Li Y, Chen R, Yuan Z, Qin Y, Huang J, Liang B, Liao Y, Ye L, Liang H, Xie Z, Jiang J.
    PLoS Negl Trop Dis; 2022 May 26; 16(5):e0010388. PubMed ID: 35507586
    [Abstract] [Full Text] [Related]

  • 11. MALDI-TOF MS-Based Clustering and Antifungal Susceptibility Tests of Talaromyces marneffei Isolates from Fujian and Guangxi (China).
    Fang L, Liu M, Huang C, Ma X, Zheng Y, Wu W, Guo J, Huang J, Xu H.
    Infect Drug Resist; 2022 May 26; 15():3449-3457. PubMed ID: 35800121
    [Abstract] [Full Text] [Related]

  • 12. Clinical characteristics, rapid identification, molecular epidemiology and antifungal susceptibilities of Talaromyces marneffei infections in Shenzhen, China.
    Lau SKP, Xing F, Tsang CC, Tang JYM, Tan YP, Ye H, Lau RWT, Chen JHK, Lo SKF, Woo PCY.
    Mycoses; 2019 May 26; 62(5):450-457. PubMed ID: 30597630
    [Abstract] [Full Text] [Related]

  • 13. Characteristics and risk factors for readmission in HIV-infected patients with Talaromyces marneffei infection.
    Shi M, Qin Y, Chen S, Wei W, Meng S, Chen X, Li J, Li Y, Chen R, Su J, Yuan Z, Wang G, Qin Y, Ye L, Liang H, Xie Z, Jiang J.
    PLoS Negl Trop Dis; 2023 Oct 26; 17(10):e0011622. PubMed ID: 37816066
    [Abstract] [Full Text] [Related]

  • 14. Talaromycosis (Penicilliosis) Due to Talaromyces (Penicillium) marneffei: Insights into the Clinical Trends of a Major Fungal Disease 60 Years After the Discovery of the Pathogen.
    Cao C, Xi L, Chaturvedi V.
    Mycopathologia; 2019 Dec 26; 184(6):709-720. PubMed ID: 31811603
    [Abstract] [Full Text] [Related]

  • 15. Clinical features of patients with talaromycosis marneffei and microbiological characteristics of the causative strains.
    Peng L, Shi YB, Zheng L, Hu LQ, Weng XB.
    J Clin Lab Anal; 2022 Nov 26; 36(11):e24737. PubMed ID: 36268985
    [Abstract] [Full Text] [Related]

  • 16. Talaromyces marneffei, Coccidioides species, and Paracoccidioides species-a systematic review to inform the World Health Organization priority list of fungal pathogens.
    Morris AJ, Kim HY, Nield B, Dao A, McMullan B, Alastruey-Izquierdo A, Colombo AL, Heim J, Wahyuningsih R, Le T, Chiller TM, Forastiero A, Chakrabarti A, Harrison TS, Bongomin F, Galas M, Siswanto S, Dagne DA, Roitberg F, Gigante V, Beardsley J, Sati H, Alffenaar JW, Morrissey CO.
    Med Mycol; 2024 Jun 27; 62(6):. PubMed ID: 38935909
    [Abstract] [Full Text] [Related]

  • 17. Development and validation of a colorimetric antifungal susceptibility testing method for the dimorphic fungus Talaromyces marneffei.
    Thu NTM, Borda H, Vitsupakorn S, Reddy KS, Kasmani N, Barwatt J, Schwartz IS, Giamberardino C, Perfect JR, Hoa NT, Le T.
    Med Mycol; 2023 Nov 06; 61(11):. PubMed ID: 37994652
    [Abstract] [Full Text] [Related]

  • 18. In Vitro Susceptibility of Berberine Combined with Antifungal Agents Against the Yeast Form of Talaromyces marneffei.
    Luo H, Pan KS, Luo XL, Zheng DY, Andrianopoulos A, Wen LM, Zheng YQ, Guo J, Huang CY, Li XY, Hu R, Li YJ, Li TM, Joseph J, Cao CW, Liang G.
    Mycopathologia; 2019 Apr 06; 184(2):295-301. PubMed ID: 30805832
    [Abstract] [Full Text] [Related]

  • 19. Innate Immunity Acts as the Major Regulator in Talaromyces marneffei Coinfected AIDS Patients: Cytokine Profile Surveillance During Initial 6-Month Antifungal Therapy.
    Dong RJ, Zhang YG, Zhu L, Liu HL, Liu J, Kuang YQ, Wang RR, Li YY.
    Open Forum Infect Dis; 2019 Jun 06; 6(6):ofz205. PubMed ID: 31211154
    [Abstract] [Full Text] [Related]

  • 20. Gastrointestinal Talaromyces marneffei infection in a patient with AIDS: A case report and systematic review.
    Ling F, Guo T, Li J, Chen Y, Xu M, Li S, Zhu L.
    Front Immunol; 2022 Jun 06; 13():980242. PubMed ID: 36248856
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.